Home / PDSB : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does PDSB make money? Does PDSB have pricing power? What's the Earnings Whisper? Will PDSB profit more as the business scales? What is PDSB's management track record? Is PDSB's current price justified?

PDS Biotechnology Corporation

$0.29 -$0.54 (-64.61%)

NASDAQ · 11 Sep 2026 20:00 UTC

Previous Close

$0.32

Day Range

$0.29$0.32

Year Range

$0.2$1.55

Market Cap

16.49M

AVG Volume

6.87M

Trailing/Forward PE

-0.46/-

PEG ratio

0.01

Dividend Yield

Next Earnings Date

2026-11-12

Primary Exchange

NASDAQ

Net Income (USD)

PDSB Net Income (USD) by year
Period	Net Income (USD)
2025	-34.5M
2024	-37.61M
2023	-42.94M
2022	-40.85M
2021	-16.92M
2020	-14.85M
2019	-7M
2018	-20.77M
2017	-50.86M
2016	-38.82M

Operating Income (USD)

PDSB Operating Income (USD) by year
Period	Operating Income (USD)
2025	-31.54M
2024	-36.32M
2023	-43.05M
2022	-41.67M
2021	-21.44M
2020	-14.67M
2019	-17.67M
2018	-38.69M
2017	-51.97M
2016	-39.51M

EBITDA (USD)

PDSB EBITDA (USD) by year
Period	EBITDA (USD)
2025	-30.3M
2024	-33.78M
2023	-40.12M
2022	-41.17M
2021	-21.43M
2020	-14.84M
2019	-7.25M
2018	-26.89M
2017	-51.08M
2016	-39.36M

Cash Flows (USD)

PDSB Cash Flows (USD) by year
Period	Cash Flows (USD)
2025	-27.75M
2024	-35.06M
2023	-33.64M
2022	-25.71M
2021	-12.49M
2020	-13.15M
2019	-18.07M
2018	-33.15M
2017	-40.89M
2016	-32.88M

EPS (USD)

PDSB EPS (USD) by year
Period	EPS (USD)
2025	-0.75
2024	-1.04
2023	-1.38
2022	-1.53
2021	-0.63
2020	-1.05
2019	-0.79
2018	-12.56
2017	-33.59
2016	-26.9

Expenses (USD)

PDSB Expenses (USD) by year
Period	Expenses (USD)
2025	31.54M
2024	36.34M
2023	43.05M
2022	41.67M
2021	21.44M
2020	14.67M
2019	16.72M
2018	30.24M
2017	52.15M
2016	40.2M

Cash & Debt (USD)

PDSB Cash & Debt (USD) by year
Period	Cash & Debt (USD)
2025	26.71M
2024	41.69M
2023	56.56M
2022	73.82M
2021	65.24M
2020	28.84M
2019	12.16M
2018	34.65M
2017	88.07M
2016	106.4M

Debt ratios

PDSB Debt ratios by year
Period	Debt ratios
2025	0.07
2024	0.15
2023	0.28
2022	0.59
2021	0.92
2020	0.28
2019	0.1
2018	0.24

Return on Capital

PDSB Return on Capital by year
Period	Return on Capital
2025	-372.85%
2024	-197.9%
2023	-164.33%
2022	-92.85%
2021	-26.77%
2020	-54.73%
2019	-59.83%
2018	-69.59%
2017	-81.54%
2016	-43.48%

Shares Outstanding

PDSB Shares Outstanding by year
Period	Shares Outstanding
2025	46.38M
2024	36.45M
2023	31.67M
2022	28.77M
2021	28.43M
2020	22.26M
2019	5.28M
2018	1.57M
2017	1.54M
2016	1.45M

Book Value Per Share (USD)

PDSB Book Value Per Share (USD) by year
Period	Book Value Per Share (USD)
2025	0.2
2024	0.52
2023	0.83
2022	1.53
2021	2.22
2020	1.22
2019	2.21
2018	18.98
2017	40.42
2016	61.74

Total Assets (USD)

PDSB Total Assets (USD) by year
Period	Total Assets (USD)
2025	30.49M
2024	45.36M
2023	59.39M
2022	77.01M
2021	67.2M
2020	30.89M
2019	14.49M
2018	36.22M
2017	92.62M
2016	110.91M

Employee Count

PDSB Employee Count by year
Period	Employee Count
2025	21
2024	24
2023	25
2022	26
2021	22
2020	15
2019	15
2018	10
2017	38
2016	31

Free Cash Flow Yield

PDSB Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	-102.25%
Sep 26	-137.06%
Aug 26	-142.97%
Aug 26	-138%
Aug 26	-130.76%
Aug 26	-53.67%
Jul 26	-60.65%
Jul 26	-61.06%
Jul 26	-56.62%
Jul 26	-53.77%
Jul 26	-48.77%
Jun 26	-46.83%
Jun 26	-43.57%
Jun 26	-39.63%
Jun 26	-40.79%
May 26	-38.53%
May 26	-34.67%
May 26	-31.05%
May 26	-47.86%
May 26	-61.01%
Apr 26	-66.44%
Apr 26	-45.67%
Apr 26	-55.4%
Apr 26	-94.22%
Mar 26	-127.23%
Mar 26	-120.63%
Mar 26	-109.16%
Mar 26	-102.36%
Feb 26	-102.04%
Feb 26	-106.3%
Feb 26	-98.29%
Feb 26	-96.34%
Jan 26	-82.71%
Jan 26	-72.51%
Jan 26	-72.41%
Jan 26	-64.37%
Jan 26	-82.67%
Dec 25	-76.18%
Dec 25	-77.38%
Dec 25	-70.71%
Dec 25	-79.17%
Nov 25	-89.34%
Nov 25	-91.18%
Nov 25	-81.95%
Nov 25	-82.22%
Oct 25	-80.07%
Oct 25	-81.42%
Oct 25	-80.83%
Oct 25	-79.04%
Oct 25	-73.4%
Sep 25	-73.4%
Sep 25	-71.31%
Sep 25	-64.54%
Sep 25	-62.39%
Aug 25	-60.38%
Aug 25	-62.92%
Aug 25	-62.92%
Aug 25	-75.93%
Aug 25	-77.33%
Jul 25	-71.43%
Jul 25	-73.29%
Jul 25	-67.97%
Jul 25	-63.37%
Jun 25	-59.78%
Jun 25	-52.03%
Jun 25	-48.16%
Jun 25	-49.87%
May 25	-61.08%
May 25	-53.35%
May 25	-59.36%
May 25	-80.15%
May 25	-69.69%
Apr 25	-76.94%
Apr 25	-89.05%
Apr 25	-93.38%
Apr 25	-101.23%
Mar 25	-76.33%
Mar 25	-69.97%
Mar 25	-77.93%
Mar 25	-77.93%
Feb 25	-72.07%
Feb 25	-71.53%
Feb 25	-61.45%
Feb 25	-65.66%
Jan 25	-58.45%
Jan 25	-61.84%
Jan 25	-66.11%
Jan 25	-67.98%
Jan 25	-53.25%
Dec 24	-56.06%
Dec 24	-58.09%
Dec 24	-52.1%
Dec 24	-44.17%
Nov 24	-43.77%
Nov 24	-45.86%
Nov 24	-47.69%
Nov 24	-28.54%
Nov 24	-29.35%
Oct 24	-30.1%
Oct 24	-28.89%

Price to Book

PDSB Price to Book by year
Period	Price to Book
Aug 26	11.05
Jul 26	9.78
Jul 26	9.71
Jul 26	10.48
Jul 26	11.03
Jul 26	12.16
Jun 26	12.67
Jun 26	13.62
Jun 26	14.97
Jun 26	14.54
May 26	15.4
May 26	17.11
May 26	19.1
May 26	6.27
May 26	4.92
Apr 26	4.51
Apr 26	6.57
Apr 26	5.41
Apr 26	3.18
Mar 26	2.68
Mar 26	2.83
Mar 26	3.13
Mar 26	3.34
Feb 26	3.35
Feb 26	3.21
Feb 26	3.47
Feb 26	3.54
Jan 26	4.13
Jan 26	4.71
Jan 26	4.72
Jan 26	5.3
Jan 26	4.13
Dec 25	4.48
Dec 25	4.41
Dec 25	4.83
Dec 25	4.31
Nov 25	3.82
Nov 25	3.75
Nov 25	4.17
Nov 25	2.62
Oct 25	2.69
Oct 25	2.64
Oct 25	2.66
Oct 25	2.72
Oct 25	2.93
Sep 25	2.93
Sep 25	3.02
Sep 25	3.34
Sep 25	3.45
Aug 25	3.57
Aug 25	3.42
Aug 25	3.42
Aug 25	2.01
Aug 25	1.98
Jul 25	2.14
Jul 25	2.08
Jul 25	2.25
Jul 25	2.41
Jun 25	2.55
Jun 25	2.94
Jun 25	3.17
Jun 25	3.06
May 25	2.5
May 25	2.86
May 25	2.57
May 25	2.3
May 25	2.65
Apr 25	2.4
Apr 25	2.07
Apr 25	1.98
Apr 25	1.82
Mar 25	2.42
Mar 25	2.29
Mar 25	2.06
Mar 25	2.06
Feb 25	2.23
Feb 25	2.24
Feb 25	2.61
Feb 25	2.44
Jan 25	2.74
Jan 25	2.59
Jan 25	2.43
Jan 25	2.36
Jan 25	3.01
Dec 24	2.86
Dec 24	2.76
Dec 24	3.08
Dec 24	3.63
Nov 24	3.66
Nov 24	3.5
Nov 24	3.36
Nov 24	3.9
Nov 24	3.8
Oct 24	3.7
Oct 24	3.86
Oct 24	4.06
Oct 24	4.4
Sep 24	4
Sep 24	3.8
Sep 24	3.56

No video analysis for this stock yet. Request one from our team.

News: PDSB

defenseworld.net · 9 Sep 2026

Traders Buy Large Volume of Call Options on PDS Biotechnology (NASDAQ:PDSB)

PDS Biotechnology Corporation (NASDAQ: PDSB - Get Free Report) was the target of some unusual options trading activity on Tuesday. Investors acquired 1,957 call options on the stock. This represents an increase of 1,154% compared to the average daily volume of 156 call options. Analyst Upgrades and Downgrades Several research firms recently issued reports on PDSB.

globenewswire.com · 8 Sep 2026

PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks

Dr. Soon-Shiong will Join PDS Biotech's Board of Directors PDS Biotech Plans to Progress Development of PDS0301 Immunocytokine in Solid Tumors PRINCETON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today announced it has raised up to $22.55 million in equity funding in a Private Investment in Public Equity (“PIPE”) transaction.

globenewswire.com · 13 Aug 2026

PDS Biotech Reports Second Quarter 2026 Financial Results

PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today provided a business and clinical programs update and reported financial results for the quarter ended June 30, 2026.

benzinga.com · 11 Aug 2026

PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program

PDS Biotechnology Corporation (NASDAQ:PDSB) shares have fallen by about 67% on Tuesday as the company announced a strategic refocus on its PDS0301 program for metastatic colorectal cancer.

globenewswire.com · 11 Aug 2026

PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101

PRINCETON, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on developing targeted immunotherapies for cancer, today issued a Letter to Shareholders from Frank Bedu-Addo, Ph.D.